ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)

This study is testing a new way to treat people with a type of blood cancer called chronic myeloid leukemia (CML) in chronic phase. This study is for the patients whose first treatment with a drug called a tyrosine kinase inhibitor (TKI; standard therapy) did not work well and resistant to the TKI drug. The study is checking if a drug called Asciminib (having different way of action), used either by itself or with another drug called Dasatinib, can be a better second option to help control the CML.

NCT Number	NCT07538401
Lead Sponsor	University Health Network, Toronto Collaborators: Novartis
Conditions	Chronic Myeloid Leukemia (CML) in
Enrollment	45 participants
Start Date	2026-04-25
Primary Completion	2028-04-25 (estimated)
Study Completion	2029-04-25 (estimated)
Updated on ClinicalTrials.gov	2026-04-20